PTC Therapeutics
PTCT
123 hedge funds and large institutions have $313M invested in PTC Therapeutics in 2016 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 33 increasing their positions, 44 reducing their positions, and 22 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
122% more call options, than puts
Call options by funds: $18.2M | Put options by funds: $8.2M
83.56% more ownership
Funds ownership: 0% → 83.56% (+84%)
41% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 22
7% more funds holding
Funds holding: 115 → 123 (+8)
23% less capital invested
Capital invested by funds: $408M → $313M (-$94.6M)
25% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$13.5M |
| 2 |
RI
RTW Investments
New York
|
+$10.5M |
| 3 |
D.E. Shaw & Co
New York
|
+$7.89M |
| 4 |
KCM
Kingdon Capital Management
New York
|
+$6.35M |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$5.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$28M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$11.5M |
| 3 |
Renaissance Technologies
New York
|
-$7.74M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$6.89M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$5.57M |
PTCT Hedge Fund Activity: Q4 2016 in Review
123 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q4 2016, worth a combined $313M — down 23% from $408M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new PTCT positions and 22 closed out — a net gain of 9 holders — while 33 added to existing stakes and 44 trimmed.
The largest buyer was Millennium Management, adding an estimated $13.5M. The largest seller was Camber Capital Management, exiting entirely with an estimated $28M sold.
- 123 institutional investors held PTC Therapeutics (PTCT) as of Q4 2016, up from 115 in Q3 2016.
- Funds reported $313M of PTC Therapeutics stock for Q4 2016, down 23% quarter-over-quarter.
- 31 funds opened new PTC Therapeutics positions in Q4 2016 and 22 closed out, a net change of +9 holders.
- The largest PTC Therapeutics buyer in Q4 2016 was Millennium Management, an estimated $13.5M added.
- The largest PTC Therapeutics seller in Q4 2016 was Camber Capital Management, an estimated $28M sold.
Based on aggregated 13F filings for Q4 2016.